ADMA BIOLOGICS, INC. Long-Term Debt, Maturity, Year Two
ADMA BIOLOGICS, INC. (ADMA) had Long-Term Debt, Maturity, Year Two of $191.56 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2026-08-05
- 2026-06-30: Long-Term Debt, Maturity, Year Two $191.56M.
- 2026-03-31: Long-Term Debt, Maturity, Year Two $191.56M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2026-06-30 | $191.56M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $191.56M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |